CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 36 enrolled
Drug / intervention
LY900014 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03341299
NCT03341299Phase 1Completed
CompareCT.gov

A Study to Evaluate the Pharmacokinetics and Glucodynamics of LY900014 Compared to Humalog® in Patients With T1DM

Eli Lilly and Company·interventional·Posted Nov 14, 2017·Updated May 14, 2020

In Brief

A Phase 1 clinical trial evaluating LY900014 and Insulin Lispro for Diabetes Mellitus, Type 1. Completed, enrolled 36 participants across 2 sites.

Detailed Summary

The purpose of this study is to evaluate a new formulation of insulin lispro, LY900014, which is a drug that lowers blood sugar. The study will look at how the body processes LY900014, and the effect of LY900014 on blood sugar levels following a standard meal. For each participant, the study will consist of 4 periods and there will be approximately 12 weeks from screening to final study follow up.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 1
CountriesGermany
Collaborators--

Timeline

Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedNov 14, 2017
Enrollment StartNov 13, 2017
Primary CompletionApr 3, 2018
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 8.6 years ago

Interventions

LY900014biological

Administered SC

Insulin Lisprobiological

Administered SC